Advanced glycation end products in diabetic complications

Current Opinion in Endocrinology and Diabetes

Volumn 3, Issue 4, 1996, Pages 291-297

  Brownlee, Michael ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001139913     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199608000-00003     Document Type: Article

References (86)

1. Nathan D: Relationship between metabolic control and long term complications of diabetes. In Joslin's Diabetes. Edited by Kahn CR, Weir G. Philadelphia: Lea & Febiger; 1994:620-631.
2. The Diabetes Control and Complications Trial Research Group: N Engl J Med 1993, 329:977.
3. Kuusisto J, Mykkanen L, et al.: NIDDM and its metabolic control predict heart disease in elderly subjects. Diabetes 1994, 960:7.
4. Hammes H-P, Martin S, Federlin K, Geisen K, Brownlee M: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A 1991, 88:11555-11558.
5. Nakayama H, Mitsuhashi T, Kuwajima S, Acki S, Kuroda Y, Itch T, Nakagawa S: Immunochemical detection of advanced glycation end products in lens crystallins from streptozotocin-induced diabetic rats. Diabetes 1993, 42:345-350.
6. Mitsuhashi T, Nakayama H, Itch S, Kuwajima S, Acki S, Atsumi T, Kioke T: Immunochemical detection of advanced glycation end products in renal cortex from STZ induced diabetic rat. Diabetes 1993, 42:826-832.
7. Beisswenger PJ, Makita Z, Curphey TJ, Moore LL, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H: Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995, 44:824-829. An important study in type I diabetic patients showing that AGEs in skin are elevated before the onset of microvascular complications and that their level correlates with the appearance of retinopathy and nephropathy.
8. Nishino T, Horri Y, Shikki H, Yamamoto H, Makita Z, Bucala R, Dohi K: Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy. Hum Pathol 1995, 26:308-313. Immunoreactive AGEs accumulate in nodular and diffuse lesions of diabetic glomeruli and also in hyaline deposits of arterioles.
9. Makino H, Shikata K, Hironaka K, Kushiro M, Yamasaki Y, Sugimoto H, Ota Z, Araki N, Horiuchi S: Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int 1995, 48:517-526. Scanning electron microscopy of AGE-positive glomerular nodules shows enlarged pore size, consistent with the pattern of glomerular permeability observed in humans.
10. Kume S, Takeya M, Mori T, Araki N, Suzuki H, Horiuchi S, Kodama T, Miyauchi Y, Takahashi K: Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol 1995, 147:654-667. Immunoreactive AGEs accumulate in human aorta, particularly in cells of atherosclerotic lesions.
11. Fu M-X, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW: Glycation, glycoxidation, and cross-linking of collagen by glucose: kinetics, mechanisms and inhibition of late stages of the Maillard reaction. Diabetes 1994, 43:676-684.
12. Giardino I, Horiuchi S, Brownlee M: Accelerated formation of extracellular advanced glycation end products (AGE's) detected by a specific monoclonal antibody. Diabetes 1994, 43:320.
13. Brownlee M: Advanced products of non-enzymatic glycosylation and the pathogenesis of diabetic complications. In Diabetes Mellitus: Theory and Practice. Edited by Rifkin H, Porte D Jr. New York: Elsevier; 1990:279-292.
14. Monnier V: Toward a Maillard reaction theory of aging. In Proceedings of the NIH Conference on the Maillard Reaction in Aging, Diabetes and Nutrition. Edited by Baynes JW, Monnier VM. New York: Liss; 1989:1-22.
15. Baynes JW, Thorpe SR, Murtiashaw MH: Nonenzymatic glycosylation of lysine residues in albumin. In Methods in Enzymology: Posttranslational Modifications, vol 106. Edited by Wold F, Moldave K. New York: Academic Press; 1984:88-98.
16. Higgins PJ, Bunn HF: Kinetic analysis of the nonenzymatic glycosylation of hemoglobin. J Biol Chem 1981, 256:5204-5208.
17. 1c. Clin Chim Acta 1983, 134:317-326.
18. Kato H, Hayase F, Shin DB, Oimomi M, Baba S: 3-Deoxyglucasone, an intermediate product of the Maillard reaction. In Proceedings of the NIH Conference on the Maillard Reaction in Aging, Diabetes and Nutrition. Edited by Baynes JW, Monnier VM. New York: Liss; 1989:69-84.
19. Kato H, Shin DB, Hayase F: 3,Deoxyglucosone cross links proteins under physiological conditions. Agric Biol Chem 1987, 51:2009-2013.
20. Kato H, Cho RK, Okitani A, Hayase F: Responsibility of 3 deoxyglucosone for the glucose induced polymerization of proteins. Agric Biol Chem 1987, 51:683-687.
21. Ohmori S, Mori M, Shiraha, K, Kawase M: In Enzymology and Molecular Biology of Carbonyl Metabolism 2. Edited by Weiner H, Flynn TG. New York: Liss; 1989:397-412.
22. Thornally PH, Atkins TW: Erythrocyte glyoxalase activity in genetically obese and streptozotocin diabetic mice. Diabetes Res 1989, 11:125-129.
23. Wolff SP, Dean RT: Glucose autoxidation and protein modification: the potential role of "autoxidative glycosylation" in diabetes. Biochem J 1987, 245:243-252.
24. Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW: Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 1995, 34:3702-3709. In vitro, glyoxal and arabinose are the intermediates in the crosslinking of proteins by glucose under oxidative conditions. However, autoxidation may be a secondary process in vivo. (See Wells-Knecht et al., Biochemistry 1995, 34:15134-15141.)
25. Wells-Knecht MC, Thorpe SR, Baynes JW: Pathways of formation of glycoxidative products during glycation of collagen. Biochemistry 1995, 34:15134-15141. Autoxidation of glucose and oxidation of glucose-derived Amadori products are two pathways that give rise to AGEs. Here, the authors show that in vivo, the Amadori adduct may be the more significant precursor of AGEs.
26. Glomb MA, Monnier VM: Mechanisms of protein modification by glyoxal and glycoaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 1995, 270:10017-10026. In vitro, approximately 50% of one AGE (carboxymethyllysine) originates from oxidation of the Amadori product, and 50% originates from other pathways.
27. Araki N, Ueno N, Chakrabarti B, Morino Y, Horiuchi S: Immunochemical evidence for the presence of advanced glycation end products in human lens protein and its positive correlation with aging. J Biol Chem 1992, 267:10211-10214.
28. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW: Formation of pentosidine during nonenzymatic browning of proteins by glucose: identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991, 266:11654-11660.
29. Horiuchi S, Araki N, Morino Y: Immunochemical approach to characterize advanced glycation end products of the Maillard reaction: evidence for the presence of a common structure. J Biol Chem 1991, 266:7329-7332.
30. Makita Z, Vlassara H, Cerami A, Bucala R: Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992, 267:5133-5138.
31. Wells-Knecht KJ, Lyons TJ, McCance DR, Thorpe SR, Feather MS, Baynes JW: 3-Deoxyfructose concentrations are increased in human plasma and urine in diabetes. Diabetes 1994, 43:1152-1156.
32. Yamada H, Miyata S, Igaki N, Yatabe H, Miyauchi Y, Ohara T, Sakai M, Shoda H, Oimomi M, Kasuga M: Increase in 3-deoxyglucosone levels in diabetic rat plasma: specific in vivo determination of intermediate in advanced Maillard reaction. J Biol Chem 1994, 269:20275-20280.
33. Takahashi M, Fujii J, Teshima T, Suzuki K, Shiba T, Taniguchi N: Identity of a major 3 deoxyglucosone reducing enzyme with aldehyde reductase in rat liver established by amino acid sequencing and cDNA expression. Gene 1993, 127:249-253.
34. Thornalley PJ: The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem J 1990, 269:1-11.
35. Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, Cerami A, Bucala R: Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 1992, 258:651-653.
36. Giardino I, Edelstein D, Brownlee M: BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation end products in bovine endothelial cells. J Clin Invest 1996, 97:1422-1428. Hyperglycemia rapidly induces an increase in intracellular AGEs in endothelial cells. This increase is inhibited by antioxidants and bcl-2 expression, indicating that a reactive oxygen species-dependent process plays a central role in the generation of intracellular AGEs.
37. Takahashi M, Lu YB, Myint T, Fujii J, Wada Y, Taniguchi N: In vivo glycation of aldehyde reductase, a major 3-deoxyglucosone reducing enzyme: identification of glycation sites. Biochemistry 1995, 34:1433-1438. 3-Deoxyglucosone is a major AGE precursor. The enzyme that reduces it to a nonreactive product is shown here to undergo glycation itself in vivo in liver and kidney. The effect of this intracellular glycation is to decrease the catalytic efficiency of the enzyme. Thus, AGEs may beget more AGEs intracellularly.
38. Bucala R, Model P, Cerami A: Modification of DNA by reduced sugars: a possible mechanism for nucleic acid aging and age-related dysfunction in gene expression. Proc Natl Acad Sci U S A 1984, 81:105-109.
39. Bucala R, Model R, Russl M, Cerami A: Modification of DNA by glucose-6-phosphate induces DNA rearrangements in an E. coli plasmid. Proc Natl Acad Sci U S A 1985, 82:8439-8442.
40. Lee AT, Cerami A: Elevated glucose-6-phosphate levels are associated with plasmid mutations in vivo. Proc Natl Acad Sci U S A 1987, 84:8311-8314.
41. Bucala R, Lee AT, Rourke L, Cerami A: Transposition of an Alu-containing element induced by DNA-advanced glycosylation endproducts. Proc Natl Acad Sci U S A 1993, 90:2666-2670.
42. Papoulis A, al-Abed Y, Bucala R: Identification of N2-(1-carboxyethyl) guanine (CEG) as a guanine advanced glycosylation end product Biochemistry 1995, 34:648-655. Advanced glycation end products are known to form on nucleotides, causing mutations and DNA transposition. Here, a major AGE nucleotide formed in vitro is identified.
43. Brownlee M, Vlassara H, Kooney T, Ulrich P, Cerami A: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986, 232:1629-1632.
44. Kent MJC, Light ND, Bailey AJ: Evidence for glucose-mediated covalent cross-linking of collagen after glycosylation in vitro. Biochem J 1985, 225:745-752.
45. Tanaka S, Avigad G, Brodsky B, Eikenberry EF: Glycation induces expansion of the molecular packing of collagen. J Mol Biol 1988, 203:495-505.
46. Brownlee M, Pongor S, Cerami A: Covalent attachment of soluble protein by nonenzymatically glycosylated collagen: role in the in situ formation of immune complexes. J Exp Med 1983, 158:1739-1744.
47. Sensi M, Tanzi P, Bruno RM, Mancuso M, Andriani D: Human glomerular basement membrane: altered binding characteristics following in vitro non-enzymatic glycosylation. Ann N Y Acad Sci 1986, 488:549-552.
48. Brownlee M, Vlassara H, Cerami A: Non-enzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes 1985, 34:938-941.
49. Tsilbary EC, Charonis AS, Reger LA, Wohlhueter RM, Furcht LT: The effect of nonenzymatic glycosylation on the binding of the main noncollagenous NC1 domain to type IV collagen. J Biol Chem 1990, 263:4302-4308.
50. Charonis AS, Reger LA, Dege JE, Kouzi-Koliakos K, Furcht LT, Wohlhueter RM, Tsilbary EC: Laminin alterations after in vitro nonenzymatic glycosylation. Diabetes 1988, 39:807-814.
51. Cochrane SM, Robinson GB: In vitro glycation of a glomerular basement membrane alters its permeability: a possible mechanism in diabetic complications. FEBS Lett 1995, 375:41-44. In vivo, AGEs are associated with enlarged pore size in glomerular nodules. Here, AGE formation on glomerular basement membrane in vitro is shown to increase permeability directly.
52. Haitoglou CS, Tsilibary EC, Brownlee M, Charonis AS: Altered cellular interactions between endothelial cells and nonenzymatically glycosylated laminin/type IV collagen. J Biol Chem 1992, 267:12404-12407.
53. Federoff HJ, Lawrence D, Brownlee M: Non enzymatic glycosylation of laminin and the laminin peptide CIKVAVS inhibits neurite outgrowth. Diabetes 1993, 42:509-513.
54. Kalfa TA, Gerritsen ME, Carlson EC, Binstock AJ, Tsilibary EC: Altered proliferation of retinal microvascular cells on glycated matrix. Invest Ophthalmol Vis Sci 1995, 36:2358-2367. Glycation of intact retinal basement membrane or isolated membrane components caused reduced retinal pericyte proliferation and increased endothelial cell proliferation, similar to what occurs in vivo.
55. Huijberts MSP, Wolffenbuttel BRH, Struijker Boudier HAJ, et al.: Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 1993, 92:1407-1411.
56. Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 1991, 87:432-438.
57. Hogan M, Cerami A, Bucala R: Advanced glycosylation end products block the antiproliferative effect of nitric oxide. J Clin Invest 1992, 90:1110-1115.
58. Vlassara H, Brownlee M, Cerami A: High-affinity receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci U S A 1985, 82:5588-5592.
59. Yang Z, Makita Z, Horii Y, Brunelle S, Cerami A, Sehajpal P, Suthanthiran M, Vlassara H: Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins. J Exp Med 1991, 174:515-524.
60. Vlassara H, Brownlee M, Monogue K, Dinarello CA, Pasagian A: Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988, 240:1546-1548.
61. Kirstein M, Aston C, Hintz R, Vlassara H: Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 1992, 90:439-446.
62. Yui S, Sasaki T, Araki N, Horiuchi S, Yamazaki M: Induction of macrophage growth by advanced glycation end products of the Maillard reaction. J Immunol 1994, 152:1943-1949.
63. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H: Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 1991, 174:931-939.
64. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ: Receptor specific increase in extracellular matrix productions in mouse mesangial cells by advanced glycosylation end products is mediated via platelet derived growth factor. Proc Natl Acad Sci U S A 1992, 89:2873-2877.
65. Vlassara H, Striker U, Teichberg S, Fuh H, Li YM, Stoffes M: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994, 91:111704-11708.
66. Yang CW, Vlassara H, Peten E, He CJ, Stricker G, Striker L: Advanced glycation end products upregulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A 1994, 91:9436-9440.
67. Schmidt AM, Vianna M, Gerlach M, et al.: Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992, 267:14987-14997.
68. Neeper M, Schmidt AM, Brett J, et al.: Cloning and expression of RAGE: a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992, 267:14998-15004.
69. Schmidt AM, Mora R, Cao K, et al.: The endothelial cell binding site for advanced glycation endproducts consists of A complex: an integral membrane protein and a lactoferrin-like polypeptide. J Biol Chem 1996, in press.
70. Esposito C, Gerlach H, Brett J, Stern D, Vlassara H: Endothelial receptor-mediated binding of glucose modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1992, 170:1387-1407.
71. Vlassara H, Fuh H, Donnelly T, Cybulsky M: Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1995, 1:447-456. Vascular endothelial cell adhesion molecule 1 is an inducible cell-cell recognition protein associated with atherogenesis. Intravenous AGEs caused VCAM-1 expression in aortas of experimental animals.
72. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995, 96:1395-1403. Advanced glycation end products induced VCAM-1 expression in cultured endothelial cells. The effect was inhibitable by blocking either the AGE receptor or by antioxidants.
73. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hon O, Stern D, Schmidt AM: Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: soluble receptor for advanced glycation endproducts blocks hyperpermeability in diabetic rats. J Clin Invest 1996, in press. Diabetes-induced increases in vascular permeability are partially reversed by blockade of the AGE receptor, and AGEs themselves increase endothelial cell permeability.
74. Yan SD, Schmidt AM, Anderson GM, et al.: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994, 269:9889-9897.
75. Edelstein D, Brownlee M: Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 1992, 41:26-29.
76. Hirsch J, Baines CL, Feather MS: X-ray structures of a 3-amino-5- and a 3-amino-6-substituted triazine, produced as a result of a reaction of 3-deoxy-o-erythro-hexos-2-ulose 3-deoxyglucosone) with aminoguanidine. J Carbohydrate Chem 1992, 11:891-901.
77. Lo TW, Selwood T, Thornalley PJ: The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins. Biochem Pharmacol 1994, 48:1865-1870.
78. Corbett JA, Tilton RG, Chang K, et al.: Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 1992, 41:552-556.
79. Hammes H-P, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K: Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 1994, 37:32-35.
80. Hammes HP, Strodter D, Weiss A, Bretzel RG, Federlin K, Brownlee M: Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model. Diabetologia 1995, 38:656-660. Aminoguanidine treatment and islet transplantation were equally effective in retarding the progression of established retinopathy in an animal model.
81. Soules-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991, 40:1328-1335.
82. Edelstein D, Brownlee M: Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 1992, 35:96-97.
83. Ellis EN, Good BH: Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism 1991, 40:1016-1019.
84. Cameron NE, Cotter MA, Dines K, Love A: Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin diabetic rats. Diabetologia 1992, 35:946-950.
85. Kihara M, Schmelzer JD, Poduslo JF, Curran GL, Nickander KK, Low PA: Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology and oxygen free radicals. Proc Natl Acad Sci U S A 1991, 88:6107-6111.
86. Zimmerman GA, Meistrell M 3rd, Bloom O, Cockroft KM, Bianchi M, Risucci D, Broome J, Farmer P, Cerami A, Vlassara H, et al.: Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A 1995, 92:3744-3748. Systemically administered AGEs increase cerebral infarct size in an animal model, whereas aminoguanidine treatment attenuates infarct size in these animals.